公开(公告)号：US20240123050A1

公开(公告)日：2024-04-18

申请号：US18310066

申请日：2023-05-01

Applicant: The Trustees of the University of Pennsylvania ,  The Johns Hopkins University ,  Vanderbilt University

Inventor： Drew Weissman ,  George M. Shaw ,  Justin R. Bailey ,  Stuart C. Ray ,  James Crowe, Jr. ,  Andrew Flyak

IPC: A61K39/12 ,  A61K9/127 ,  A61K39/29 ,  A61K39/39 ,  A61P31/14

CPC classification number: A61K39/12 ,  A61K9/127 ,  A61K39/29 ,  A61K39/39 ,  A61P31/14 ,  A61K9/0019

Abstract: The present invention relates to compositions and methods for inducing an adaptive immune response against Hepatitis C virus (HCV) in a subject. In some embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof. For example, in some embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof.

公开(公告)号：US11957749B2

公开(公告)日：2024-04-16

申请号：US16772194

申请日：2018-12-14

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Virginia Ammendola ,  Babak Bayat ,  Clarisse Lorin ,  Ventzislav Bojidarov Vassilev ,  Alessandra Vitelli

IPC: A61K39/29 ,  A61K39/39 ,  A61P31/20 ,  C07K14/005 ,  C12N7/00 ,  A61K39/00

CPC classification number: A61K39/292 ,  A61K39/39 ,  A61P31/20 ,  C07K14/005 ,  C12N7/00 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/55555 ,  A61K2039/55572 ,  A61K2039/55577 ,  A61K2039/57 ,  C07K2319/40 ,  C12N2710/10343 ,  C12N2710/24143 ,  C12N2730/10122 ,  C12N2730/10134

Abstract: The present invention relates to immunogenic compositions and combinations thereof which may find use in immunisation regimens for the treatment of chronic hepatitis B. An immunogenic composition comprises a replication-defective chimpanzee adenoviral (ChAd) vector comprising polynucleotides encoding HBs, HBc human invariant chain (hIi) fused to the HBc. Another immunogenic composition comprises a Modified Vaccinia Virus Ankara (MVA) vector comprising polynucleotides encoding HBs and HBc. Another immunogenic composition comprises recombinant HBs, C-terminal truncated recombinant HBc and an adjuvant containing MPL and QS-21.

公开(公告)号：US11957657B2

公开(公告)日：2024-04-16

申请号：US17368161

申请日：2021-07-06

Applicant: Trustees of Tufts College

Inventor： William W. Bachovchin ,  Hung-sen Lai ,  Wengen Wu

IPC: A61K31/402 ,  A61K31/4025 ,  A61K31/4035 ,  A61K31/4439 ,  A61K31/69 ,  A61K35/13 ,  A61K39/39 ,  A61K45/06 ,  A61P35/00 ,  A61P37/04 ,  A61K39/00

CPC classification number: A61K31/402 ,  A61K31/4025 ,  A61K31/4035 ,  A61K31/4439 ,  A61K31/69 ,  A61K35/13 ,  A61K39/39 ,  A61K45/06 ,  A61P35/00 ,  A61P37/04 ,  A61K2039/505 ,  A61K31/69 ,  A61K2300/00

Abstract: Disclosed are combination therapies including administration of I-DASH inhibitors and PGE2 antagonists, and the use of such therapies in the treatment of cell proliferative diseases.

公开(公告)号：US20240115681A1

公开(公告)日：2024-04-11

申请号：US18476345

申请日：2023-09-28

Applicant: National Health Research Institutes

Inventor： Tsung-Hsien Chuang ,  Jing-Xing Yang ,  Jen-Chih Tseng ,  Zaida Nur Imana ,  Ming-Hsi Huang ,  Guann-Yi Yu

IPC: A61K39/00 ,  A61K9/00 ,  A61K39/39 ,  A61P31/16 ,  A61P35/00

CPC classification number: A61K39/001111 ,  A61K9/0019 ,  A61K9/0043 ,  A61K39/39 ,  A61P31/16 ,  A61P35/00 ,  A61K2039/543 ,  A61K2039/55561

Abstract: Provided is a pharmaceutical composition including an active pharmaceutical ingredient, a toll-like receptor (TLR) agonist, a stimulator of interferon genes (STING) agonist, and a pharmaceutically acceptable carrier. Also provided are a method for inducing immune response and a method for treating or preventing cancer or an infectious disease, including administering an effective amount of the pharmaceutical composition to a subject in need thereof.

公开(公告)号：US11951163B2

公开(公告)日：2024-04-09

申请号：US18178638

申请日：2023-03-06

Applicant: Valneva Austria GmbH

Inventor： Jana Barbero Calzado ,  Mario Nebenführ ,  Robert Schlegl ,  Michael Weber ,  Jürgen Heindl-Wruss

IPC: A61K39/12 ,  A61K9/00 ,  A61K39/00 ,  A61K39/39 ,  A61P31/14 ,  C07K14/18 ,  C12N7/00 ,  C12N7/02 ,  C12N7/06

CPC classification number: A61K39/12 ,  A61K39/39 ,  A61P31/14 ,  C07K14/18 ,  C07K14/1825 ,  C12N7/00 ,  C12N7/02 ,  C12N7/06 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/5258 ,  A61K2039/55505 ,  C12N2770/24134 ,  C12N2770/24151 ,  C12N2770/24163 ,  Y02A50/30

Abstract: Described herein are Zika virus vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.

公开(公告)号：US20240108720A1

公开(公告)日：2024-04-04

申请号：US18264046

申请日：2022-02-02

Applicant: ACM BIOLABS PTE LTD

Inventor： Madhavan NALLANI ,  Jian Hang LAM ,  Thomas Andrew CORNELL ,  Amit Kumar KHAN ,  LIam Thomas MARTIN

IPC: A61K39/39 ,  A61K47/34 ,  A61P37/04

CPC classification number: A61K39/39 ,  A61K47/34 ,  A61P37/04 ,  A61K2039/55561

Abstract: The present invention relates to eliciting an immune response in a subject by sole administration of an adjuvant, wherein the adjuvant is associated with a population of polymersomes.

公开(公告)号：US20240108714A1

公开(公告)日：2024-04-04

申请号：US18227796

申请日：2023-07-28

Applicant: American Gene Technolgies Internationl Inc.

Inventor： Charles David Pauza ,  Haishan Li ,  Tyler Lahusen ,  Jeffrey A. Galvin

IPC: A61K39/21 ,  A61K31/7105 ,  A61K35/14 ,  A61K39/12 ,  A61K39/39 ,  A61K45/06 ,  A61P31/18 ,  C07K14/715 ,  C12N5/078 ,  C12N5/0783 ,  C12N7/00 ,  C12N15/11 ,  C12N15/113 ,  C12N15/86

CPC classification number: A61K39/21 ,  A61K31/7105 ,  A61K35/14 ,  A61K39/12 ,  A61K39/39 ,  A61K45/06 ,  A61P31/18 ,  C07K14/7158 ,  C12N5/0634 ,  C12N5/0636 ,  C12N7/00 ,  C12N15/111 ,  C12N15/1132 ,  C12N15/1138 ,  C12N15/86 ,  A61K35/17 ,  C12N2330/51 ,  C12N2710/24143 ,  C12N2740/16022 ,  C12N2740/16034 ,  C12N2740/16043

Abstract: The present invention relates generally to immunization and immunotherapy for the treatment or prevention of HIV. In particular, the methods include in vivo and/or ex vivo enrichment of HIV-specific CD4+ T cells.

公开(公告)号：US20240101719A1

公开(公告)日：2024-03-28

申请号：US18276761

申请日：2022-02-11

Applicant: Universidade Catolica Portuguesa-UCP ,  Amyris Bio Products Portugal, Unipessoal LDA

Inventor： Joao Cruz Fernandes ,  Maria Manuela Faria Amorim ,  Pedro Miguel Constante De Sousa ,  Diana Maria Tavares Valente ,  Joao Pedro Azevedo Silva ,  Christopher J. Paddon ,  Maria Manuela Estevez Pintado

IPC: C08B37/00 ,  A61K39/39 ,  A61P37/04

CPC classification number: C08B37/0003 ,  A61K39/39 ,  A61P37/04 ,  C08B37/0009 ,  C08B37/0024 ,  A61K2039/55583

Abstract: The present disclosure relates to method of obtaining high purity glucans, in particular yeast glucans with immunomodulatmy properties, including vaccine adjuvant properties for the use as adjuvant in vaccines.

公开(公告)号：US20240100144A1

公开(公告)日：2024-03-28

申请号：US18476042

申请日：2023-09-27

Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Maria A. CROYLE ,  Stephen Clay SCHAFER

IPC: A61K39/12 ,  A61K39/39 ,  C12N7/00 ,  C12N15/88

CPC classification number: A61K39/12 ,  A61K39/39 ,  C12N7/00 ,  C12N15/88 ,  A61K2039/543

Abstract: Immunogenic compositions comprising viral vectors and surfactants are provided. Methods for administration and preparation of such compositions are also provided.

公开(公告)号：US11938177B2

公开(公告)日：2024-03-26

申请号：US17517597

申请日：2021-11-02

Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Services

Inventor： Robert Seder ,  Geoffrey Lynn

IPC: A61K39/00 ,  A61K9/00 ,  A61K39/39 ,  A61P35/00 ,  B82Y5/00

CPC classification number: A61K39/0011 ,  A61K9/0019 ,  A61K39/001102 ,  A61K39/39 ,  A61P35/00 ,  A61K2039/555 ,  A61K2039/55555 ,  A61K2039/60 ,  A61K2039/6093 ,  B82Y5/00

Abstract: Embodiments of a novel platform for delivering a peptide antigen to a subject to induce an immune response to the peptide antigen are provided. For example, nanoparticle polyplexes are provided that comprise a polymer linked to a peptide conjugate by an electrostatic interaction. The conjugate comprises a peptide antigen linked to a peptide tag through an optional linker. An adjuvant may be included in the nanoparticle polyplex, linked to either the polymer or the conjugate, or admixed with the nanoparticles. The nanoparticle polyplex can be administered to a subject to induce an immune response to the peptide antigen.